|
|
|
|
|
|
|
|
|||||
 |
|
James
Cardon, PhD The Effects of Direct-to-Consumer Pharmaceutical Advertising March
19, 2004 |
|
Biosketch:
James Cardon graduated from Brigham Young University in with a B.A. in Economics. After completing his M.A. and Ph.D. form Princeton University, James returned to BYU to teach Economics; he is currently an Associate Professor of Economics at Brigham Young University. His fields of interests include Industrial Organization, Health Economics, and Econometrics. In
1997, the FDA relaxed regulations on direct-to-consumer (DTC) advertising
for pharmaceutical products. This has led to a substantial increase in
such expenditures which in turn raises some important public policy questions.
We examine the effects of DTCA on pharmaceutical adherence in three therapeutic
classes: antidepressants, statins, and diabetes. We find some evidence
that DTCA raises adherence measures in our sample, but the effects are
modest, and in some DTCA appears to lower adherence.
|
|
|